Clinical trials: Patients With Type 1 or Type 2 Diabetes
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
The purpose of this study is to help answer the following research question(s): To test if taking LY2599506 for 12 weeks controls blood sugar better than taking glyburide for 12 weeks.
- Trial name
- NCT01029795
- Testing
- LY2599506, Glyburide
- Where
- 16 sites in Australia, Austria and 5 more
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication.
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity.
- Trial name
- NCT03010956
- Where
- Greece
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Athens
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Diabetes Mellitus, Coronary Heart Disease
Long-term Mortality in Diabetics Undergoing Major Surgery
Patients with CAD and diabetes mellitus have a better prognosis than patients with CAD and no diabetes mellitus. In acute coronary syndrome patients with an insulin therapy had a better survival than patients with oral…
- Conditions
- Diabetes Mellitus, Coronary Heart Disease, Major Non-cardiac Surgery
- Trial name
- NCT00286572
- Where
- Switzerland
- Volunteers
- 380 people
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00665093
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,569 people
- Sponsor
- Novo Nordisk A/S
Adult Patients With Type 2 Diabetes
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and…
- Trial name
- NCT06871761
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Diabetic Retinopathy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic…
- Trial name
- CANBERRA (NCT04265261)
- Testing
- RG7774
- Where
- 68 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 1
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes
This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542463
- Testing
- insulin detemir
- Where
- Germany
- Volunteers
- 4,464 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
- Trial name
- NCT07004153
- Testing
- Smart Coaching Insulin Pen
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- G2e Co., Ltd
Patients With Type 1 or 2 Diabetes, Lesion Situated on a Toe or on the Plantar or Dorsal Side of the Foot
Impact of Malnutrition on the Healing of Foot Lesions in Diabetic Patients
The investigators set out to determine whether malnutrition delayed healing of foot lesions in diabetic patients.
- Trial name
- NCT02168348
- Testing
- biological examination at consultations at 3 and 6 months
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Type 1 Diabetes, Type 2 Diabetes
Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device
The primary objective of this study is to compare patient preference of the h-Patch as delivery device for insulin lispro compared with either an insulin pen or needle and syringe in patients with diabetes, either Type 1 or Type…
- Trial name
- NCT00453934
- Testing
- h-Patch
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Valeritas, Inc.
Diabetes Type 1 or 2 With Diabetic Retinopathy
Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.
The aim of this study is to show that PRPC performed in a single session using a Pascal laser leads to better management of the disease (better rate of regression of neovessels, lower risk of a loss of visual acuity in the long…
- Trial name
- Pascal (NCT01766362)
- Testing
- PRPC using Pascal laser
- Where
- 3 sites in France
- Volunteers
- 83 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetes Mellitus
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI…
- Trial name
- NCT00135941
- Testing
- insulin glargine, insulin glulisine
- Where
- United States
- Volunteers
- 582 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Local Registration Trial in China Humalog Mix 50
The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in insulin-requiring diabetic patients treated twice daily with human insulin mix 50/50, versus the 2-hour PPBG excursion…
- Trial name
- NCT00191581
- Testing
- Humalog Mix 50, Human Insulin Mix 50:50
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Swiss Diabetes Registry - SwissDiab Study
Currently, the estimated number of people with diabetes mellitus is approximately 387 million people worldwide. Due to population growth, urbanization, ageing and the rising prevalence of obesity the numbers of individuals with…
- Trial name
- SwissDiab (NCT01179815)
- Where
- 4 sites in Switzerland
- Volunteers
- 1,500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern